title: Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987.
abstract: Between January 1982 and December 1987, of 283 children with neuroblastoma treated in the Pediatric Department of Institut Gustave Roussy, 34 were stage IV-S. Two groups were distinguished according to the initial clinical presentation: 16/34 patients had life-threatening symptoms and needed immediate treatment, and 18/34 had no life-threatening symptoms. Hepatic irradiation was used in 12/16 patients of the first group with respiratory distress. Chemotherapy was used in three patients. Of these 16 patients, three patients died of progressive disease (one patient died of a reason not related to the tumor). Twelve are alive in first complete remission and one in second complete remission. Of the 18 patients of the second group, eight had spontaneous complete remission, and one of them relapsed thereafter and died despite treatment. Ten patients needed treatment, radiotherapy, and/or chemotherapy depending on the site of disease progression. Two of them died of the disease. The overall disease-free survival for these 34 patients is 75% at 90 months postdiagnosis. Using this therapeutic strategy, it was possible to avoid any treatment of metastases in 25% of the patients.
authors.affiliation: Department of Pediatrics, Institut Gustave Roussy, Villejuif, France.
authors.forename: A
authors.initials: A
authors.lastname: Suarez
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
authors.forename: G
authors.initials: G
authors.lastname: Vassal
authors.forename: A
authors.initials: A
authors.lastname: Giron
authors.forename: J L
authors.initials: JL
authors.lastname: Habrand
authors.forename: D
authors.initials: D
authors.lastname: Valteau
authors.forename: L
authors.initials: L
authors.lastname: Brugieres
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: J
authors.initials: J
authors.lastname: Lemerle
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008113:Liver Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D009365:Neoplasm Regression, Spontaneous; D009447:Neuroblastoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D013713:Teniposide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D013713:Teniposide